Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models

References

• Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356–14. doi:10.1038/s41571-019-0175-7.
   PubMed Web of Science ®Google Scholar
• Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450–465. doi:10.1016/j.ccell.2023.02.014.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118. doi:10.1038/cr.2016.151.
   PubMed Web of Science ®Google Scholar
• Itahashi K, Irie T, Nishikawa H. Regulatory T-cell development in the tumor microenvironment. Eur J Immunol. 2022;52(8):1216–1227. doi:10.1002/eji.202149358.
   PubMed Web of Science ®Google Scholar
• Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018;33(4):649–663.e4. doi:10.1016/j.ccell.2018.02.010.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, Lebbé C, Svane IM, McNeil C, Rutkowski P, et al. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. J Immunother Cancer. 2020;8(1):e000391. doi:10.1136/jitc-2019-000391.
   PubMed Web of Science ®Google Scholar
• Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008;8(12):970–976. doi:10.1038/nri2438.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, et al. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021;9(5):e002535. doi:10.1136/jitc-2021-002535.
   PubMed Web of Science ®Google Scholar
• Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2018;283(2):110–120. doi:10.1111/joim.12708.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria J-C, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. doi:10.1158/1078-0432.CCR-16-1741.
   PubMed Web of Science ®Google Scholar
• Kas B, Talbot H, Ferrara R, Richard C, Lamarque J-P, Pitre-Champagnat S, Planchard D, Balleyguier C, Besse B, Mezquita L, et al. Clarification of definitions of hyperprogressive disease during immunotherapy for non–small cell lung cancer. JAMA Oncol. 2020;6(7):1039–1046. doi:10.1001/jamaoncol.2020.1634.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346–1358. doi:10.1038/s41590-020-0769-3.
   PubMed Web of Science ®Google Scholar
• Wakiyama H, Kato T, Furusawa A, Okada R, Inagaki F, Furumoto H, Fukushima H, Okuyama S, Choyke PL, Kobayashi H, et al. Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after PD-1 blockade therapy. Cancer Immunol Res. 2022;10(11):1386–1397. doi:10.1158/2326-6066.CIR-22-0041.
   PubMed Web of Science ®Google Scholar
• Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, et al. PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116(20):9999–10008. doi:10.1073/pnas.1822001116.
   PubMed Web of Science ®Google Scholar
• Gorka AP, Nani RR, Schnermann MJ. Cyanine polyene reactivity: scope and biomedical applications. Org Biomol Chem. 2015;13(28):7584–7598. doi:10.1039/C5OB00788G.
   PubMed Web of Science ®Google Scholar
• Usama SM, Inagaki F, Kobayashi H, Schnermann MJ. Norcyanine-carbamates are versatile near-infrared fluorogenic probes. J Am Chem Soc. 2021;143(15):5674–5679. doi:10.1021/jacs.1c02112.
   PubMed Web of Science ®Google Scholar
• Nani RR, Gorka AP, Nagaya T, Yamamoto T, Ivanic J, Kobayashi H, Schnermann MJ. In vivo activation of duocarmycin-antibody conjugates by near-infrared light. ACS Cent Sci. 2017;3(4):329–337. doi:10.1021/acscentsci.7b00026.
   PubMed Web of Science ®Google Scholar
• Nagaya T, Gorka AP, Nani RR, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Schnermann MJ, Kobayashi H. Molecularly targeted cancer combination therapy with near-infrared photoimmunotherapy and near-infrared photorelease with duocarmycin–antibody conjugate. Mol Cancer Ther. 2018;17(3):661–670. doi:10.1158/1535-7163.MCT-17-0851.
   PubMed Web of Science ®Google Scholar
• Vargas FA, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity. 2017;46(4):577–586. doi:10.1016/j.immuni.2017.03.013.
   PubMed Web of Science ®Google Scholar
• Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke PL, Hasegawa Y, Kobayashi H. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci Transl Med. 2016;8(352):352ra110. doi:10.1126/scitranslmed.aaf6843.
   PubMed Web of Science ®Google Scholar
• Okada R, Furusawa A, Vermeer DW, Inagaki F, Wakiyama H, Kato T, Nagaya T, Choyke PL, Spanos WC, Allen CT, et al. Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. EBioMedicine. 2021;67:103345. doi:10.1016/j.ebiom.2021.103345.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Furusawa A, Kato T, Wakiyama H, Takao S, Okuyama S, Choyke PL, Kobayashi H. Intratumoral IL15 improves efficacy of near-infrared photoimmunotherapy. Mol Cancer Ther. 2023;22(10):1215–1227. doi:10.1158/1535-7163.MCT-23-0210.
   PubMedGoogle Scholar
• Fukushima H, Kato T, Furusawa A, Okada R, Wakiyama H, Furumoto H, Okuyama S, Kondo E, Choyke PL, Kobayashi H, et al. Intercellular adhesion molecule-1-targeted near-infrared photoimmunotherapy of triple-negative breast cancer. Cancer Sci. 2022;113(9):3180–3192. doi:10.1111/cas.15466.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Takao S, Furusawa A, Valera Romero V, Gurram S, Kato T, Okuyama S, Kano M, Choyke PL, Kobayashi H, et al. Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer. Cancer Lett. 2024;585:216606. doi:10.1016/j.canlet.2023.216606.
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116(7):1935–1945. doi:10.1172/JCI27745.
   PubMed Web of Science ®Google Scholar
• Cibrian D, Sanchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47(6):946–953. doi:10.1002/eji.201646837.
   PubMed Web of Science ®Google Scholar
• Vendetti FP, Pandya P, Clump DA, Schamus-Haynes S, Tavakoli M, diMayorca M, Islam NM, Chang J, Delgoffe GM, Beumer JH, et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight. 2023;8(4):e165615. doi:10.1172/jci.insight.165615.
   PubMed Web of Science ®Google Scholar
• Majri SS, Fritz JM, Villarino AV, Zheng L, Kanellopoulou C, Chaigne-Delalande B, Grönholm J, Niemela JE, Afzali B, Biancalana M, et al. STAT5B: a differential regulator of the life and death of CD4+ effector memory T cells. J Immunol. 2018;200(1):110–118. doi:10.4049/jimmunol.1701133.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Turkbey B, Pinto PA, Furusawa A, Choyke PL, Kobayashi H. Near-infrared photoimmunotherapy (NIR-PIT) in urologic cancers. Cancers. 2022;14(12):2996. doi:10.3390/cancers14122996.
   PubMed Web of Science ®Google Scholar
• Yang Y, Jin G, Pang Y, Huang Y, Wang W, Zhang H, Tuo G, Wu P, Wang Z, Zhu Z, et al. Comparative efficacy and safety of nivolumab and nivolumab plus ipilimumab in advanced cancer: a systematic review and meta-analysis. Front Pharmacol. 2020;11:40. doi:10.3389/fphar.2020.00040.
   PubMed Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. doi:10.1186/s13046-019-1259-z.
   PubMed Web of Science ®Google Scholar
• Zhulai G, Oleinik E. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy. Scand J Immunol. 2022;95(3):e13129. doi:10.1111/sji.13129.
   PubMed Web of Science ®Google Scholar
• Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6(1):57. doi:10.1186/s40425-018-0360-8.
   PubMed Web of Science ®Google Scholar
• Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, Shyer JA, Zhang Z, Mittman S, Gutierrez A, et al. Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nat Commun. 2023;14(1):4703. doi:10.1038/s41467-023-40398-4.
   PubMed Web of Science ®Google Scholar
• Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2016;39:1–6. doi:10.1016/j.coi.2015.10.009.
   PubMed Web of Science ®Google Scholar
• Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61. doi:10.1186/s13045-022-01282-8.
   PubMed Web of Science ®Google Scholar
• Gui P, Ben-Neji M, Belozertseva E, Dalenc F, Franchet C, Gilhodes J, Labrousse A, Bellard E, Golzio M, Poincloux R, et al. The protease-dependent mesenchymal migration of tumor-associated macrophages as a target in cancer immunotherapy. Cancer Immunol Res. 2018;6(11):1337–1351. doi:10.1158/2326-6066.CIR-17-0746.
   PubMed Web of Science ®Google Scholar
• Kato T, Fukushima H, Furusawa A, Okada R, Wakiyama H, Furumoto H, Okuyama S, Takao S, Choyke PL, Kobayashi H, et al. Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response. Oncoimmunol. 2022;11(1):2152248. doi:10.1080/2162402X.2022.2152248.
   PubMed Web of Science ®Google Scholar
• Gorka AP, Schnermann MJ. Harnessing cyanine photooxidation: from slowing photobleaching to near-IR uncaging. Curr Opin Chem Biol. 2016;33:117–125. doi:10.1016/j.cbpa.2016.05.022.
   PubMed Web of Science ®Google Scholar